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Available online 3 February 2016The Genea017 human embryonic stem cell line was derived from a donated, fully commercially consented ART
blastocyst, carrying Htt gene CAG expansion of 40 repeats, indicative of Huntington Disease. Following ICM out-
growth on inactivated human feeders, genetic analysis conﬁrmed a 46, XY karyotype and male allele pattern
through CGH and STR analysis. The hESC line had pluripotent cell morphology, 87% of cells expressed Nanog,
95%Oct4, 88% Tra1-60 and 99% SSEA4, gave a PluriTest pluripotency score of 34.74, novelty of 1.27, demonstrated
alkaline phosphatase activity and tri-lineage teratoma formation. The cell line was negative forMycoplasma and
visible contamination.
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Cell line derivation
The embryo was plated whole onto mitomycin C inactivated human
feeders (Detroit 551 HFF – 200,000 cells per organ culture dish –
69,204 cells/cm2) in 20% KSR medium with 50 ng/mL FGF added fresh
(Amit et al., 2000). Karyotyping and STR proﬁling were performed at
the ﬁrst cryobanking step from ICM outgrowths maintained on feeders.
Alkaline phosphatase staining and teratoma formation were performed
from feeders. Cells were then enzymatically passaged as single cells in
M2 pluripotent cell maintenance medium (Genea Biocells) for freezing
of single cell stocks and karyotyping/DNAproﬁlingwas repeated aswell
as immunoﬂuorescent pluripotent marker staining, PluriTest and steril-
ity testing were performed.se (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
CGH analysis summary; Genea017 (passage 12, 2 enzymatic) reporting a male cell line
and no abnormalities detected.
CGH summary
Sample name Genea017 p12_2
Date reported 22nd July 2013
Hybridisation balance Balanced hybridisation was observed for all chromosomes,
relative to reference DNA
Copy number change No copy number changes above 400 kb were detected
Interpretation Male cell line — no abnormalities detected
Fig. 1. Morphology and karyotype of Genea017. A) Brightﬁeld (passage 2) growing on
human inactivated feeders. B) Alkaline phosphatase activity (passage 35) on human
inactivated feeders. C) Karyotypic analysis (passage 5) showing 46, XY normal, male
karyotype.
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1. Karyotyping: Passage 5; for enrichment of metaphase cells, cellular
outgrowths were incubated with either 0.22 ng/mL colcemid
(Invitrogen) and 37.5 g/mL BrdU (Sigma) for 17–19 h or 5 ng/mL
colcemid for 2.5 h. Single cells were subsequently obtained using
Non-Enzymatic Cell Dissociation Solution (Sigma) and transferred
to Sydney IVF's (now Genea) diagnostic cytogenetics laboratory
for preparation of metaphase spreads and cytogenetic analysis by
G-banding. A minimum of 15 metaphase cells were examined, of
which a full karyotype or chromosome counts were performed for
5 and 10 of the metaphases respectively.
2. Comparative genomic hybridisation (CGH) based chromosomal
analysis: Passage 12 (10 on feeders, 2 enzymatic); CGH was used to
screen targeted regions of the genome for gains and losses associated
with chromosomal imbalances such as aneuploidy, deletions and du-
plications. CGH was performed using SurePrint G3 microarrays
(8 × 60 K format) which were scanned with the Agilent Scanner C
and analysed using Genomic Workbench Standard Edition 5.0 soft-
ware (Agilent Technologies).3. DNA proﬁling: Passage 5; DNA ‘ﬁngerprinting’ was performed using
the AmpFLSTR Identiﬁler PCR Ampliﬁcation Kit (Applied Biosystems
#4322288) to provide permanent genetic identiﬁcation of the
cell lines (https://www.thermoﬁsher.com/order/catalog/product/
4322288).
Pluripotency assessment
1. Alkaline phosphatase: Passage 35; Genea017 grown on feeders were
stained as per manufacturer's protocol using the Merck Millipore Al-
kaline Phosphatase Detection Kit (SCR004).
2. Immunoﬂuorescence: Passage 12 (10 on feeders, 2 enzymatic); cells
were ﬁxed with formalin and stained with Nanog #560483 1:200;
Oct4 #560217 1:150; Tra1-60 #560121 1:150; SSEA4 #560308
1:200 (all BD Pharmingen). Images were acquired with an IN Cell
Analyser 6000 and quantiﬁed using In Cell Developer Software (GE).
3. PluriTest: Passage 12 (10 on feeders, 2 enzymatic); RNA was collect-
ed and subjected to a PluriTest, a bioinformatic assay of pluripotency
in human cells based on gene expression proﬁles (Müller et al.,
2012).
4. Teratoma formation: Passage 43; two CB17-SCID mice sourced from
the Animal Resource Centre (ARC) in Western Australia. Stem cells
were received oneday prior to injection andharvested usingCollage-
nase IV treatment, washed in DMEM/F12 and resuspended in injec-
tion buffer supplemented with 10% FBS and 30% BD Matrigel™. In
both experiments, micewere anaesthetised before intramuscular in-
jection of the cells into the hind leg of the mouse. Approximately
1 × 106 cells (1 × T25) in 50 μL were injected per mouse at one site
only. Resultant teratomas were excised, ﬁxed, sectioned and stained
for assessment of tissues from each of the embryonic germ layers.
Sterility testing
1. Mycoplasma: Passage 10; testing was performed at the Victorian
Infectious Diseases Reference Laboratory using Mycoplasma genus
PCR.
2. Microbial contamination: Testing was performed in conjunction
with our QC measures. Cells were thawed and cultured in 7 mL anti-
biotic free medium (Genea Biocells M2 medium) for 2–3 days at
37 °C. A clear solution at ~48–72h indicated a lack of bacterial, fungal
or yeast contamination. Clarity of the solution was assessed by the
Cell Production Team.
Veriﬁcation and authentication
Ethics/consents
Ethics approval for the project (‘Derivation of human embryonic
stem cells from embryos identiﬁed through pre-implantation genetic
diagnosis to be affected by known genetic conditions’) was obtained
from the Genea Ethics Committee on 13 September 2005. Excess ART
embryoswere fully consented for stem cell derivation by all responsible
people through an informed consent process (signed de-identiﬁed con-
sent form can be provided upon request). Donors have received no pay-
ment or ﬁnancial beneﬁts for their donation. Genea017 has been
Table 2
STR proﬁle; Genea017 (passage 5) demonstrating male allele pattern.
D8S1179 D21S11 D7S820 CSF1PO D3S1358 TH01 D13S317 D16S539 D2S1338 D19S433 vWA TPOX D18S51 D5S818 FGA
SIVF17 13,15 29 10,12 12 14,18 9 8,14 11,12 17,18 14,15 15,18 8,11 15,18 12,13 21,23
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ly created by assisted reproduction technology (ART) for the purpose
of procreation. The embryowas identiﬁed through pre-implantation ge-
netic diagnosis to be affected by a geneticmutation andwas declared an
excess to reproductive needs. Derived was performed under Australian
National Health and Medical Research Council (NHMRC) licence
309710. This licence was issued to Genea on 7 May 2007. More in-
formation about the licence can be obtained from the NHMRCwebpage
at http://www.nhmrc.gov.au/health-ethics/human-embryos-and-
cloning/database-licences-authorising-use-excess-art-embryos.
PGD analysis conclusion
Mutation; expansion of CAG (12 and 40 CAG repeats) in HTT gene.
Family tree; Mother; b inherited from her Mother; bwho in turn
inherited from her Father. Huntington Disease (HD) affected. See
Bradley et al. (2011) for sequencing analysis.
Morphology
The derived stem cell line, Genea017, morphologically displays
an adherent monolayer of compact cells in well-deﬁned colonies withFig. 2.Pluripotency validation ofGenea017. A) Immunoﬂuorescent staining (10×)of pluripoten
enzymatic). B) Quantitation of expression of pluripotent markers. C) PluriTest pluripotency (le
D) Tri-lineage teratoma formation (passage 43) with (left) ectodermally derived neuroepith
endodermally derived glandular epithelium.a high nuclear to cytoplasmic ratio and prominent nucleoli (Fig. 1A
and B).
Genetic analysis
The cell line has been karyotyped demonstrating 46, XY (Fig. 1C,
Supplementary Fig. 1), conﬁrmed by CGH (Table 1, Supplementary
Fig. 2) consistent with the original derivation and pre-implantation ge-
netic diagnosis (PGD). Analysis of STRmarkers showed an allele pattern
consistent with the male genotype (Table 2, Supplementary Fig. 3).
Pluripotency
Genea017 is pluripotent by:
1. Alkaline phosphatase stain positivity (Fig. 1B)
2. Immunoﬂuorescence with 87% Nanog positive, 95% Oct4, 88% Tra1-
60 and 99% SSEA4 positive (Fig. 2A, quantiﬁed in Fig. 2B)
3. PluriTestwith a pluripotency score of 34.74 and novelty score of 1.27
(Fig. 2C)
4. Teratoma formation which contained tissues derived from each of
the embryonic germ layers: endoderm, mesoderm, and ectoderm
(Fig. 2D)t cellmarkers SSEA4 (green),Nanog (red), Oct3/4 (green) and Tra1/60 (red), (passage 12, 2
ft) and novelty (right) scores with Genea017 (passage 12, 2 enzymatic) outlined in black.
elium (middle), choroid plexus, mesodermally derived cartilage and bone (right) and
496 B. Dumevska et al. / Stem Cell Research 16 (2016) 493–496Sterility
The cell line is tested and found negative for Mycoplasma and any
visible contamination (Supplementary Fig. 4).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2016.02.007.
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